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PAX genes have been shown to be critically required for the development of speciﬁc tis-
sues and organs during embryogenesis. In addition, PAX genes are expressed in a handful
of adult tissues where they are thought to play important roles, usually different from those
in embryogenesis. A common theme in adult tissues is a requirement for PAX gene expres-
sion in adult stem cell maintenance or tissue regeneration.The connections between adult
stem cell PAX gene expression and cancer are intriguing, and the literature is replete with
examples of PAX gene expression in either situation. Here we systematically review the
literature and present an overview of postnatal PAX gene expression in normal and can-
cerous tissue.We discuss the potential link between PAX gene expression in adult tissue
and cancer. In addition, we discuss whether persistent PAX gene expression in cancer is
favorable or unfavorable.
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INTRODUCTION
The PAX/Pax (paired box) gene family is now recognized as poten-
tially playing important roles in cancer progression (reviewed in
Robson et al., 2006). The family comprises nine transcription fac-
tors in humans (PAX1–PAX9) andmice (Pax1–Pax9) that are often
described as cell-lineage-speciﬁc regulators of tissues where their
expression is normally found. PAX gene family members share
highly similar structural motifs, evolutionarily conserved among
orthologs present in worms, ﬂies, frogs, ﬁsh, and birds (Vorobyov
and Horst, 2006). Relationships between PAX genes in terms of
their sequence homologies and evolutionary phylogeny are shown
in Figure 1. The pivotal roles of Pax during development are fur-
ther exempliﬁed by loss-of-function Pax mutant mouse models,
many of which demonstrate prenatal or early postnatal lethal-
ity (reviewed in Wang et al., 2008). The expression and role of
Pax genes during embryogenesis and tumorigenesis has previ-
ously been reviewed extensively (Chi and Epstein, 2002; Robson
et al., 2006; Wang et al., 2008). However, upon completion of
organogenesis the expression of most Pax genes attenuates, while
in some tissues Pax gene expression either continues into adult-
life or re-expression is possible (Table 1). The presence of Pax
gene expression in adult tissues is often linked with stem cell-like
properties and tissue repair, depending on the tissue context (see
below). Although features of Pax expression in adult tissues may
potentially confer signiﬁcant functions on speciﬁc cells in these tis-
sues, their speciﬁc roles in adult tissue inmany cases remain largely
unexplored.With their expression proﬁles often ﬁnely tuned both
spatially and temporally, one would predict that deregulated Pax
gene expression could therefore disrupt tissue homeostasis and
contribute to diseases such as cancer (Maulbecker andGruss, 1993;
Muratovska et al., 2003).
Each of the nine PAX family members has been associated with
multiple cancer types (Robson et al., 2006). PAX gene expression is
often found in cancer types that originate from tissues that require
PAX gene expression during development or in homeostasis (see
Table 1). Together, these data suggest that PAX gene expression
may be deregulated in cancer, but at least in some cases PAX
gene expression is a carry-over of normal expression in normal
adult tissues. It is now clear that PAX genes can either promote
or inhibit tumorigenesis. This minireview will focus on speciﬁc
examples of the role of PAX gene expression in adult tissues and
PAX gene expression in cancer. In addition, we will discuss evi-
dence supporting hypothesized functions of PAX gene expression
in cancer.
PAX EXPRESSION IN ADULT TISSUES AND IN CANCER
PAX gene expression is relatively uncommon in adult tissues, and
re-expression occurs only under certain circumstances. Pax gene
knockout mice generally die either prenatally or soon after birth
(Wang et al., 2008), which creates difﬁculties for investigating Pax
gene functions in adult tissues unless conditional or tissue-speciﬁc
knockouts are available. In some cases (i.e., Pax2, Pax3, and Pax6)
Pax genes demonstrate haploinsufﬁciency (Epstein et al., 1991;
Hill et al., 1991; Favor et al., 1996), and research has focused
on their functions in adult tissues using heterozygous Pax mouse
models (see below). PAX gene expression in adult tissues is often
associated with tissue homeostasis. Table 1 summarizes current
knowledge of PAX gene expression in adult tissues. There are two
main types: (1) continuing expression from organogenesis, and
(2) recurring expression under certain physiological conditions.
During embryogenesis and in adult tissues a frequent role of PAX
gene expression appears to be to maintain stem or progenitor cell
state (plasticity) before cells fully commit to their fate, whether
this is during organogenesis, or in tissue regeneration. However,
the exact role that PAX expression plays in stem cell maintenance
is not yet clear, but one possibility that we discuss below is that
PAX8 might maintain the capacity of cells to enter the cell cycle,
whilst simultaneously inhibiting senescence (Li et al., 2011a).
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FIGURE 1 | Representation of sequence similarities between the Pax
genes, and their possible evolution. It is thought that the Pax4 and Pax6
genes are derived from an early ancestral Pax gene, and that from this
ancestral Pax gene the ancestor of the Pax2, Pax5, and Pax8 genes was
subsequently derived, followed by the ancestors of the Pax3 and Pax7 genes,
and the Pax1 and Pax9 genes (Miller, 1999).
Table 1 | Continuing and recurring expression of PAX genes in adult tissues.
Gene Continuing expression Recurring expression* Reference
PAX1 Thymus – Peters et al. (1995), Wallin et al. (1996)
PAX2 Brain, pancreas, eye, female genital tract,
breast, lymphocytes
Kidney, prostate Stoykova and Gruss (1994), Ritz-Laser et al. (2000), Chu et al. (2001),
Silberstein et al. (2002), Tong et al. (2006, 2007), Chen et al. (2010)
PAX3 Brain, skin, skeletal muscle – Stoykova and Gruss (1994), Relaix et al. (2006), He et al. (2010)
PAX4 – Pancreas, eye, pineal gland Brun et al. (2004), Rath et al. (2009a,b)
PAX5 Brain, B-lymphocytes, lung, testis – Stoykova and Gruss (1994), Nutt et al. (1997), Adams et al. (1992)
PAX6 Brain, pancreas Eye, brain (olfactory) Stoykova and Gruss (1994), Sivak et al. (2000), Guo et al. (2010)
PAX7 Brain, skeletal muscle – Stoykova and Gruss (1994), Relaix et al. (2006)
PAX8 Thyroid, kidney, placenta, female genital
tract, lymphocytes
Pancreas Zannini et al. (1992), Ferretti et al. (2005), Rieck et al. (2009),Tong et al.
(2009), Ozcan et al. (2011)
PAX9 Thymus, esophagus – Peters et al. (1995)
*Recurring expression includes minimally detected expression.
PAX1
Pax1 is expressed in a small fraction of cortical cells in the adult
thymus (Peters et al., 1995;Wallin et al., 1996), where it is required
for thematuration of thymocytes. Expression of Pax1 in adult thy-
mus epitheliumpromotes the thymusmicroenvironment required
for normal T cell maturation.
In cervical cancer tissues PAX1 was one of six genes that were
shown to be hypermethylated (Lai et al., 2008). Moreover, parallel
testing for human papillomavirus (HPV) and PAX1 methylation
status in cervical swabs conferred an improved sensitivity than
HPV testing alone.
PAX2
PAX2 is expressed in the medullary regions of adult kidneys, and
in the transitional urothelium of the ureter and bladder wall
(Tong et al., 2006). PAX2 is also expressed in the epithelial lin-
ing of the fallopian tube in females (Tong et al., 2007) and in the
epithelium of themale genital tract from the Rete testis to the ejac-
ulatory duct (Tong et al., 2011). In female mice, Pax2 is expressed
during puberty in the mammary tubular epithelium (Silberstein
et al., 2002), and is required for progesterone-dependent mam-
mary development (Silberstein et al., 2002). PAX2 participates as
part of a complex with estrogen receptor to regulate the ERBB2
promoter (Hurtado et al., 2008).
In addition, PAX2 is expressed in the glucagon-expressing cells
of the pancreas (Ritz-Laser et al., 2000), and Pax2 expression has
been demonstrated in the optic tectum inmice (Nakamura, 2001).
Recurring Pax gene expression is important for tissue repair and
regeneration. While embryonic Pax2 gene expression has already
largely attenuated in the adult kidney cortex, four independent
groups have demonstrated that upon kidney injury, Pax2 expres-
sion re-emerges at the initial stage of tubular regeneration, in a
transient and temporally restricted pattern. The recurring expres-
sion is also proposed to confer a protective function, preventing
tubular cells from apoptosis in the initial stage of regeneration
(Imgrund et al., 1999; Maeshima et al., 2002; Cohen et al., 2007;
Huang et al., 2011). Chen et al. (2010) have also shown that
androgen-dependent re-expression of Pax2 occurs after castration
in male mice.
PAX2 is expressed in ovarian cancers, in renal cell carcinomas
(RCC), and in some bladder carcinomas (Muratovska et al., 2003;
Tong et al., 2007; Herlitz et al., 2008). In these cell types it appears
to be important for tumor cell survival (Muratovska et al., 2003;
Hueber et al., 2006), which has recently been shown to be because
PAX2 regulates ADAM10 (Doberstein et al., 2011), and in RCC
PAX2 expression is promoted by the loss of VHL and hypoxia
(Luu et al., 2009).
PAX2 is also expressed in breast cancer (Silberstein et al.,
2002), where it is important for maintaining the estrogen receptor
responsiveness of breast cancer. In breast cancer cells an estro-
gen receptor-PAX2 complex regulates ERBB2, and determines
response to tamoxifen (Hurtado et al., 2008). In addition, PAX2
expression is required for tamoxifen-induced endometrial car-
cinogenesis (Wuet al., 2005),and loss of PAX2expression enhances
endometrial cancer malignancy (Monte et al., 2010; Roh et al.,
2010). Aberrant expression of PAX2 has also been observed in
Frontiers in Genetics | Cancer Genetics January 2012 | Volume 3 | Article 6 | 2
Li and Eccles PAX genes in cancer
prostate cancer (Khoubehi et al., 2001). In addition, PAX2 expres-
sion is associated with resistance to apoptosis in Kaposi’s sarcoma
cells (Buttiglieri et al., 2004).
PAX3
Pax3 is expressed in a pool of stem cells in adult muscle, called
satellite cells (reviewed in Buckingham and Relaix, 2007). The
Pax3 gene is also expressed inmelanocyte stemcells (melanoblasts)
localized in the bulge region of hair follicles in adult skin (Lang
et al., 2005). In this location Pax3 is involved in a transcriptional
regulatory network to maintain the undifferentiated state of the
melanocyte stem cells (Lang et al., 2005). Interestingly,PAX3 is also
expressed in adult human epidermal melanocytes (He et al., 2010;
Medic and Ziman, 2010), but in this location it appears PAX3 has
retained only some of its developmental roles.
PAX3 undergoes chromosome rearrangement with FOXO1 in
the majority of alveolar rhabdomyosarcomas (Galili et al., 1993;
Bennicelli et al., 1999). In addition, PAX3 is persistently expressed
in embryonal rhabdomyosarcomas (Frascella et al., 1998). PAX3
expression has been reported in melanomas (Scholl et al., 2001;
He et al., 2010), where it was initially thought that PAX3 expres-
sion is required for the regulation of MITF gene expression, as in
the developing neural crest (reviewed in Kubic et al., 2008). MITF
is a dominant regulator in the maintenance of plasticity during
differentiation in both eye and melanoblast development (Jack-
son and Raymond, 1994). In both eye and melanocyte precursors
Pax2, Pax3, and Pax6 have been shown to transcriptionally acti-
vate the Mitf promoter activity (Watanabe et al., 1998; Baumer
et al., 2003). Indeed, Pax3–Mitf genetic interactions were shown
to act as a nodal point for maintaining embryonic and adult
stem cell plasticity (Lang et al., 2005). However, the silencing
of PAX3 expression in metastatic melanoma cells had unexpect-
edly little or no effect on MITF mRNA and protein expression
(He et al., 2011), and indeed PAX3 was only minimally bound
to the MITF promoter in melanoma cells (Medic and Ziman,
2010).
PAX4
Although there has been a lack of studies relating to the associ-
ation of Pax4 in both adult and cancer tissues, two independent
studies have reported that Pax4 re-expression confers a protec-
tive function in pancreatic β-cells (Brun et al., 2004; Lu et al.,
2007). The mitogen induced Pax4 expression not only increased
β-cell replicative potential, it also protects cells from apoptosis,
through transcriptionally activating both the oncogene c-myc and
the anti-apoptotic geneBcl-xL expression, respectively (Brun et al.,
2004).
PAX4 expressionwas shown to be upregulated in human insuli-
nomas (Miyamoto et al., 2001), and was proposed to be a survival
factor in rat insulinoma cells, through upregulating Bcl-xl expres-
sion (Brun et al., 2007). In contrast, ectopic PAX4 expression in
melanoma reduced cell growth, which suggested a possible tumor
suppressor role in melanoma (Hata et al., 2008).
PAX5
PAX5 is expressed during B lymphopoiesis, and plays an essen-
tial role in early B, pre-B and pro-B lymphocyte development,
particularly in the developmental pathway controlling V-to-DJ
recombination (Nutt et al., 1997; Sanz et al., 2003). Interestingly,
re-programming of mature B-cells to pluripotency requires PAX5
knockdown in addition to expression of Oct4, Sox2, Klf4, and
c-Myc (Hanna et al., 2008).
PAX5 expression is observed in most B-cell neoplasms, includ-
ing B-cell lymphoma (Krenacs et al., 1998). In contrast, PAX5
haploinsufﬁciency synergizes with STAT5 activation to induce
acute lymphoblastic leukemia (Heltemes-Harris et al., 2011). In
hepatocellular carcinoma PAX5 has been identiﬁed as a novel
tumor suppressor through interactingwith the p53 signaling path-
way (Liu et al., 2011). Consistent with this, overexpression of PAX5
induces apoptosis in multiple myeloma cells (Proulx et al., 2010).
PAX5 is expressed in medulloblastoma (Kozmik et al., 1995), and
in a sub-type of neuroblastoma (Baumann Kubetzko et al., 2004),
perhaps reﬂecting the earlier requirement for PAX5 expression
in the mid/hindbrain boundary during embryogenesis (Urbanek
et al., 1994). PAX5 expression in breast cancer cells enhances
epithelial behavior (Vidal et al., 2010), and has been associated
with a signiﬁcantly better prognosis than breast cancers where
PAX5 is not expressed.
PAX6
Pax6 is re-expressed in the corneal epithelium during corneal
wound repair (Sivak et al., 2000). However deﬁciency of Pax6
expression during corneal wound repair is correlated with
reduced cornea epithelial cell adhesion, elevated cell prolifera-
tion, increased stromal cells apoptosis (Ramaesh et al., 2005,
2006; Ou et al., 2010), and defective corneal neuronal migration
(Leiper et al., 2009), suggesting that Pax6 suppresses proliferation
and enhances differentiation. Similarly, during olfactory epithe-
lial regeneration, Pax6 gene expression is transiently elevated in
globose basal cells, which comprise the putative stem cell pool
to commit to either neuronal and epithelial cell lineages during
regeneration (Guo et al., 2010). PAX6 has been referred to as a neu-
roectoderm cell fate determinant (Zhang et al., 2010). Interestingly
it was shown that PAX6 protein level is essential for controlling the
balance between neural stem cell self-renewal and neurogenesis
(Sansom et al., 2009).
In the early stages of bladder cancer, and in invasive breast
cancer,PAX6-associated CpG islands become progressively hyper-
methylated, and this is associated with increased PAX6 expression
(Salem et al., 2000; Hellwinkel et al., 2008; Moelans et al., 2011).
PAX6 expression was shown to suppress the growth of human
glioblastoma cells (Zhou et al., 2005), suppressing their invasive-
ness and expression of matrix-metalloproteinase 2 (Mayes et al.,
2006), and increasing glioma cell susceptibility to detachment and
oxidative stress (Chang et al., 2007), as well as reducing angio-
genesis (Zhou et al., 2010). However, PAX6 was not apparently
mutated in gliomas (Pinto et al., 2007). In contrast, PAX6 was
expressed in pancreatic adenocarcinoma, downregulated upon
terminal differentiation (Lang et al., 2008), and actively par-
ticipated in cancer progression through activation of the MET
tyrosine kinase receptor gene (Mascarenhas et al., 2009). In addi-
tion, endogenous and lentiviral-mediated PAX6 expression pro-
moted cell proliferation and inhibited apoptosis in retinoblastoma
cells (Bai et al., 2011; Li et al., 2011b), as well as promoting
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breast cancer cell proliferation and tumorigenesis (Zong et al.,
2011).
PAX7
In adult muscle Pax7 is expressed in the muscle satellite cells, a
stem cell pool. The satellite cells are required for tissue repair and
regeneration following muscle injury (reviewed in Buckingham
and Relaix, 2007), and Pax7 expression is required to maintain
survival and proliferation of postnatal satellite cells (Relaix et al.,
2006).
PAX7 undergoes chromosome rearrangement with FOXO1 in
alveolar rhabdomyosarcomas, in a similar fashion to, although less
frequently than PAX3 (Galili et al., 1993; Bennicelli et al., 1999).
PAX8
PAX8 is expressed in the adult thyroid and kidney (Zannini et al.,
1992; Tong et al., 2009), and its role in adult thyroid tissue remains
the same as in the developing thyroid; regulating Tg (thyroglob-
ulin), Tpo (thyroid peroxidase), and NIS (sodium/iodide sym-
porter) expression, all of which are essential for thyroid hormone
synthesis (reviewed inDe Felice andDi Lauro, 2011). Interestingly,
Oct4 expression, a stem cellmarker in adult thyroid, coincideswith
a subset of Pax8 positive cells, but not Tg positive cells (which rep-
resent differentiated cells; Thomas et al., 2006). These observations
suggest that Pax8 has a separate role in the maintenance of adult
thyroid stem or progenitor cells. Similarly, in adult kidneys PAX8
is expressed in the Bowman’s capsule, and in medullary regions
(Tong et al., 2009; Li et al., 2011a), which have been proposed to be
sites of renal stem and/or progenitor cells (reviewed in Little and
Bertram, 2009), although the functional role of PAX8 in the adult
kidney has yet to be explored.
PAX8 undergoes chromosome rearrangement with PPARγ in
thyroid adenocarcinomas (Kroll et al., 2000). PAX8 was also iden-
tiﬁed in a systematic screen as a lineage survival factor for ovarian
cancer cells (Hibbs et al., 2004; Bowen et al., 2007; Cheung et al.,
2011), possibly relating to its critical role during the development
of the fetal Mullerian duct (Mittag et al., 2007). In renal, ovarian
and thyroid cancers, we recently showed that PAX8 is required
for basal E2F1 transcription and thus the capacity for entry into
the cell cycle, and also formaintaining the stability of its transcrip-
tional c-factor,RB (Li et al., 2011a). Either overexpression or loss of
E2F1 ultimately results in apoptosis or senescence (Qin et al., 1994;
Dimri et al., 2000; Berton et al., 2005; Park et al., 2006), potentially
explaining why senescence is observed when PAX8 expression is
knocked down using siRNAs in cancer cell lines. Expression of
PAX8 has also been shown to regulate telomerase, an important
factor in cellular aging and immortalization, in glioblastoma cell
lines (Chen et al., 2008).
PAX9
Like Pax1, Pax9 is expressed in the adult thymus (Peters et al.,
1995), and Pax9 expression is also required for permanent tooth
development (Suda et al., 2011). In addition,PAX9 cDNAhas been
isolated from adult human esophagus (Peters et al., 1997).
PAX9 expressionhas been shown tomediate oncogene-induced
cell survival in oral squamous cell carcinoma (Lee et al., 2008).
On the other hand progressive loss of PAX9 expression correlates
with increasing malignancy in esophageal cancers (Gerber et al.,
2002). PAX9 was shown to be ampliﬁed and highly expressed in
lung cancer tissues (Kendall et al., 2007), and in addition, pair-
wise overexpression of genes within the ampliﬁed DNA, including
PAX9,was synergistic inpromoting theproliferationof lung cancer
cell lines.
CONCLUDING REMARKS
It is widely accepted that tumor formation is an aberrant form
of organogenesis in adult tissues. Although PAX expression is
relatively rare in adult tissues, evidence suggests this expression
may be involved in maintaining pluripotency and survival of stem
cell populations. Either continuing or recurring PAX expression
is essential to provide pools of progenitor cells for tissue regen-
eration upon injury. In cancer cells, achieving self-sufﬁciency in
growth signals and unrestricted replicative potential requires that
they are able to survive in potentially adverse microenvironments
during tumor progression. There are now numerous studies that
imply that PAX genes play important roles in conferring growth
and survival advantages to cancer cells, and that they regulate cell
plasticity.
Conceptually, proliferation and differentiation are placed at
opposite ends of the “spectrum” of tumor progression. Yet, PAX
genes, such as PAX8, could play key roles in balancing these
processes. Clearly, more studies will be required to better under-
stand the role that PAX genes play in adult tissues and in
cancer.
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